JP2011524906A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524906A5
JP2011524906A5 JP2011514619A JP2011514619A JP2011524906A5 JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5 JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
thiazolo
pyridin
phenylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524906A (ja
JP5571073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003666 external-priority patent/WO2009154775A1/en
Publication of JP2011524906A publication Critical patent/JP2011524906A/ja
Publication of JP2011524906A5 publication Critical patent/JP2011524906A5/ja
Application granted granted Critical
Publication of JP5571073B2 publication Critical patent/JP5571073B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514619A 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用 Expired - Fee Related JP5571073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7447608P 2008-06-20 2008-06-20
US61/074,476 2008-06-20
PCT/US2009/003666 WO2009154775A1 (en) 2008-06-20 2009-06-18 S1p1 receptor agonists and use thereof

Publications (3)

Publication Number Publication Date
JP2011524906A JP2011524906A (ja) 2011-09-08
JP2011524906A5 true JP2011524906A5 (enExample) 2012-08-02
JP5571073B2 JP5571073B2 (ja) 2014-08-13

Family

ID=41434357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514619A Expired - Fee Related JP5571073B2 (ja) 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用

Country Status (10)

Country Link
US (2) US20120129828A1 (enExample)
EP (1) EP2306994B1 (enExample)
JP (1) JP5571073B2 (enExample)
AR (1) AR072185A1 (enExample)
AU (1) AU2009260726B2 (enExample)
CA (1) CA2728046A1 (enExample)
ES (1) ES2433579T3 (enExample)
MX (1) MX2010013555A (enExample)
TW (1) TW201000099A (enExample)
WO (2) WO2009154775A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485153B (zh) * 2010-01-13 2015-05-21 Sanofi Aventis 2,5,7-經取代唑并嘧啶衍生物
TWI478929B (zh) * 2010-01-13 2015-04-01 Sanofi Aventis 含2,5,7-經取代唑并嘧啶環之羧酸衍生物
UY33178A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico heteroxíclicos que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
MY156476A (en) 2010-01-14 2016-02-26 Sanofi Sa Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
AR079885A1 (es) 2010-01-14 2012-02-29 Sanofi Aventis Derivados de oxazolo[5,4-d]pirimidina 2,5-sustituidos utiles para el tratamiento del sindrome del pie diabetico(dfs), composiciones farmaceuticas que los contienen y proceso para prepararlos.
PT2523962E (pt) * 2010-01-14 2014-02-06 Sanofi Sa Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
EP2688882B1 (en) * 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
US9906186B2 (en) * 2012-07-20 2018-02-27 Mitsubishi Electric Corporation Holding frame and solar cell module
JP2016509036A (ja) 2013-02-20 2016-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト Mknk1阻害剤としての置換イミダゾ[1,2−b]ピリダジン
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド S1p1活性を調節するための化合物およびその使用法
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
WO2021101854A1 (en) * 2019-11-19 2021-05-27 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN115611793A (zh) * 2021-07-14 2023-01-17 山东新华制药股份有限公司 硫代酰胺类化合物的合成方法
CN116410213A (zh) * 2023-02-21 2023-07-11 武汉大学 一种合成3-碳基-1-硼基环类化合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
CA2424870A1 (en) 2000-10-05 2003-04-04 Takeda Chemical Industries, Ltd. Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
AU2004234067B2 (en) * 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
BRPI0410439A (pt) * 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
EP2939674A1 (en) 2004-10-13 2015-11-04 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
JP2009520688A (ja) * 2005-11-23 2009-05-28 エピックス デラウェア, インコーポレイテッド S1p受容体調節化合物およびそれらの使用
US20090182003A1 (en) 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
TW200806675A (en) 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
CN101379433B (zh) 2006-02-08 2012-05-30 柯达图形通信有限责任公司 含有苯并*唑衍生物及其类似物作为敏化剂的紫外线敏感的平版印版前体
US7790707B2 (en) * 2006-03-21 2010-09-07 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
US20100016387A1 (en) 2006-12-11 2010-01-21 Avirup Bose Method of treatment
JP5191497B2 (ja) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ,インコーポレイテッド S1p受容体調節化合物およびその使用
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk (3−硫黄原子置換フェニル)へテロアリール誘導体
AU2008302746B2 (en) * 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders

Similar Documents

Publication Publication Date Title
JP2011524906A5 (enExample)
JP2013527202A5 (enExample)
JP2013512900A5 (enExample)
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
JP2013512899A5 (enExample)
JP2020506171A5 (enExample)
JP2013531028A5 (enExample)
JP2017530983A5 (enExample)
JP2014526549A5 (enExample)
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
JP2004525179A5 (enExample)
JP2009500443A5 (enExample)
NZ597241A (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
JP2017511794A5 (enExample)
JP2014062126A5 (enExample)
EA016687B8 (ru) Производные циклопропиламида
NZ590839A (en) Treatment of pulmonary arterial hypertension
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
JP2007502265A5 (enExample)
JP2009532438A5 (enExample)
JP2010533131A5 (enExample)
JP2020532550A5 (enExample)
RU2009144846A (ru) Использование модулятора рецептора s1p
JP2022545698A (ja) アペリン受容体アゴニストのための方法および使用